Frank P. Zemlan

Vorstandsvorsitzender bei Phase 2 Discovery, Inc.

Health Technology

Consumer Services

Profil

Frank P.
Zemlan is Chief Executive Officer of Phase 2 Discovery, Inc. He has over 20 years of experience in clinical research at Merck & Co., Inc., Aventis, Inc., and GlaxoSmithKline Plc.
Dr. Zemlan holds a PhD.

Aktive Positionen von Frank P. Zemlan

Unternehmen	Position	Beginn
Phase 2 Discovery, Inc. Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.	Vorstandsvorsitzender	-

Alle aktiven Positionen von Frank P. Zemlan

Ehemalige bekannte Positionen von Frank P. Zemlan

Unternehmen	Position	Ende
Aventis, Inc.	Corporate Officer/Principal	-
GSK PLC	Corporate Officer/Principal	-
MERCK & CO., INC.	Corporate Officer/Principal	-

Sehen Sie sich die Erfahrung von Frank P. Zemlan im Detail an

Ausbildung von Frank P. Zemlan

Villanova University	Graduate Degree
University of Pennsylvania	Doctorate Degree

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Frank P. Zemlan im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Börsennotierte Unternehmen	2
MERCK & CO., INC.	Health Technology
GSK PLC	Health Technology

Private Unternehmen	2
Phase 2 Discovery, Inc. Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.	Health Technology
Aventis, Inc.